リンパ浮腫診断市場：世界の産業規模、シェア、動向、機会、予測、技術別、疾患別、エンドユーザー別、地域別、競合別セグメント、2019-2029年

世界のリンパ浮腫診断市場は、2023年に3,501万米ドルと評価され、2029年までのCAGRは7.83%で、予測期間中に目覚ましい成長を予測しています。

病状の領域では、リンパ浮腫は、身体の様々な部位における組織の腫脹によって典型的に特徴付けられる慢性疾患であり、腕と脚が最も一般的な罹患部位です。この症状は、リンパ系へのダメージの結果として現れることが多く、乳がんの治療後に発症することもあります。リンパ節への損傷を伴う外科的処置やその他の病歴がある場合、リンパ浮腫の同定はしばしば極めて明白です。

市場促進要因

リンパ浮腫の発生率の増加

ヘルスケアインフラの成長

認識と教育の向上

患者中心の医療

主な市場課題

限られた認知度

複雑な診断

診断機器の高コスト

主な市場動向

ポータブル・ウェアラブル機器

予防スクリーニング

遺伝子・バイオマーカー検査

目次

第1章 概要

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 顧客の声

第5章 世界のリンパ浮腫診断市場展望

• 市場規模・予測
  • 金額別
• 市場シェア・予測
  • 技術別（生体インピーダンス分析、コンピューター断層撮影、リンパシンチグラフィー、磁気共鳴画像、近赤外蛍光画像、超音波画像、X線リンパ造影）
  • 疾患別（がん、心血管疾患、炎症性疾患）
  • エンドユーザー別（診断センター、病院、調査・学術機関、その他）
  • 地域別
  • 企業別（2023）
• 製品市場マップ
  • 技術別
  • 疾患別
  • エンドユーザー別
  • 地域別

第6章 北米のリンパ浮腫診断市場展望

• 市場規模・予測
  • 金額別
• 市場シェア・予測
  • 技術別
  • 疾患別
  • エンドユーザー別
  • 国別
• 北米：国別分析
  • 米国
  • カナダ
  • メキシコ

第7章 欧州のリンパ浮腫診断市場展望

• 市場規模・予測
  • 金額別
• 市場シェア・予測
  • 技術別
  • 疾患別
  • エンドユーザー別
  • 国別
• 欧州：国別分析
  • ドイツ
  • 英国
  • フランス
  • イタリア
  • スペイン

第8章 アジア太平洋地域のリンパ浮腫診断市場展望

• 市場規模・予測
  • 金額別
• 市場シェア・予測
  • 技術別
  • 疾患別
  • エンドユーザー別
  • 国別
• アジア太平洋地域：国別分析
  • 中国
  • 日本
  • インド
  • オーストラリア
  • 韓国

第9章 南米のリンパ浮腫診断市場展望

• 市場規模・予測
  • 金額別
• 市場シェア・予測
  • 技術別
  • 疾患別
  • エンドユーザー別
  • 国別
• 南米：国別分析
  • ブラジル
  • アルゼンチン
  • コロンビア

第10章 中東・アフリカのリンパ浮腫診断市場展望

• 市場規模・予測
  • 金額別
• 市場シェア・予測
  • 技術別
  • 疾患別
  • エンドユーザー別
  • 国別
• 中東・アフリカ：国別分析
  • 南アフリカ
  • サウジアラビア
  • アラブ首長国連邦
  • クウェート

第11章 市場力学

• 促進要因
• 課題

第12章 市場動向と発展

• 最近の動向
• 合併と買収
• 製品上市

第13章 ポーターのファイブフォース分析

• 業界内の競合
• 新規参入の可能性
• サプライヤーの力
• 顧客の力
• 代替品の脅威

第14章 競合情勢

• Shimadzu Corp
• Fluoptics SAS
• Bio Compression Systems Inc
• Lohmann & Rauscher International GmbH & Co KG
• Mego Afek A.C. Ltd.
• Sigvaris Inc
• PAUL HARTMANN AG
• Stryker Corp
• Cardinal Health Inc
• ConvaTec Inc

第15章 戦略的提言

第16章 調査会社について・免責事項

Global Lymphedema Diagnostics Market was valued at USD 35.01 Million in 2023 and is anticipated to project impressive growth in the forecast period with a CAGR of 7.83% through 2029. In the realm of medical conditions, lymphedema is a chronic ailment typically marked by tissue swelling in various parts of the body, with the arms and legs being the most commonly affected areas. This condition often emerges as a consequence of damage to the lymphatic system, and it can also occur subsequent to treatments for breast cancer. In cases where there is a history of surgical procedures or other conditions involving harm to the lymph nodes, the identification of lymphedema is often quite evident.

Key Market Drivers

Rising Incidence of Lymphedema

Lymphedema, a chronic condition characterized by the abnormal swelling of body parts due to a disruption in the lymphatic system, is on the rise. The increasing incidence of lymphedema can be attributed to various factors, including cancer treatments, surgery, trauma, and infections. This growing prevalence of lymphedema is not just a cause for concern but also presents an opportunity for the Global Lymphedema Diagnostics Market to thrive.

Before delving into the factors driving market growth, it's essential to understand what lymphedema is. Lymphedema occurs when the lymphatic system, responsible for draining excess fluid from tissues, becomes compromised. This often leads to the accumulation of lymph fluid, causing swelling and discomfort, which can affect various body parts, most commonly the arms and legs.

Cancer diagnoses have been steadily rising, and fortunately, advances in cancer treatments have improved patient survivability rates. However, many cancer treatments, including surgery and radiation therapy, can inadvertently damage the lymphatic system, increasing the risk of developing lymphedema. This has resulted in a higher incidence of lymphedema, necessitating better diagnostics.

Lymphedema becomes more prevalent with age, and as the global population ages, the number of individuals at risk for developing this condition also grows. The elderly are more likely to require lymphedema diagnostics, thus contributing to market growth.

Medical practitioners and patients are increasingly aware of the importance of early detection and intervention in managing lymphedema. This awareness has led to a surge in demand for diagnostic services, fostering the growth of the lymphedema diagnostics market.

Advances in medical technology have revolutionized the diagnosis of lymphedema. Innovative imaging techniques, such as lymphoscintigraphy and advanced ultrasound, have improved diagnostic accuracy and precision. Early diagnosis can lead to more effective treatment and management, spurring the market's expansion.

In the age of information, patients are more empowered and educated about their health. They are seeking timely and accurate diagnostics, driving healthcare providers to offer comprehensive lymphedema diagnostic solutions.

Advocacy groups, healthcare organizations, and government agencies are working together to raise awareness about lymphedema. These campaigns reduce the stigma associated with the condition, encourage early diagnosis, and promote the use of diagnostic services.

Improved healthcare infrastructure, especially in developing regions, has increased access to healthcare services, including lymphedema diagnostics. This expansion of healthcare facilities ensures that more patients can seek timely diagnosis and treatment.

Growing Healthcare Infrastructure

Lymphedema, a chronic condition characterized by the abnormal swelling of body parts due to a disruption in the lymphatic system, poses a significant healthcare challenge. Early diagnosis is crucial for effective management and better patient outcomes. One key driver for the growth of the Global Lymphedema Diagnostics Market is the expansion and improvement of healthcare infrastructure.

Lymphedema diagnostics involve the use of various medical tools and techniques to identify and assess the presence and severity of lymphedema. These diagnostics are essential for healthcare providers to develop personalized treatment plans and help patients manage this condition effectively.

The growth of healthcare infrastructure in developing regions has significantly increased the accessibility of healthcare services, including diagnostics. As healthcare facilities become more widespread and accessible, individuals have a greater opportunity to seek early diagnosis and treatment for lymphedema.

With the development of healthcare infrastructure comes access to advanced medical technology. Modern diagnostic tools, such as high-resolution ultrasound and lymphoscintigraphy, provide accurate and precise assessments of lymphedema. This not only aids in early detection but also allows for tailored treatment plans.

The expansion of healthcare infrastructure often includes the training and deployment of qualified healthcare professionals. These professionals are equipped to diagnose lymphedema accurately and provide patients with the necessary guidance for effective management.

Growing healthcare infrastructure enables the implementation of preventive and educational programs. These initiatives increase awareness about lymphedema and its early signs, encouraging individuals to seek diagnostic services sooner. Timely diagnosis can lead to better patient outcomes and lower healthcare costs in the long run.

In regions with well-developed healthcare infrastructure, patients have greater access to a wide range of treatment options, from conservative measures like compression garments to more advanced therapies like manual lymphatic drainage. Effective treatment can only be provided after proper diagnosis, highlighting the importance of healthcare infrastructure.

Many countries with robust healthcare infrastructure offer reimbursement policies that cover the cost of lymphedema diagnostics. This significantly reduces the financial burden on patients, encouraging them to seek early diagnosis.

Increased Awareness and Education

Lymphedema, a chronic condition characterized by the abnormal swelling of body parts due to a disrupted lymphatic system, poses unique healthcare challenges. Timely diagnosis is paramount for effective management, and one key driver of the Global Lymphedema Diagnostics Market is the increasing awareness and education about this condition.

Lymphedema is a medical condition that affects millions of people worldwide. It can occur as a result of cancer treatment, surgery, trauma, infection, or it can be a primary condition. While it is often a lifelong concern, early diagnosis and intervention can significantly improve a patient's quality of life.

Historically, lymphedema has been a misunderstood and stigmatized condition. However, with increased awareness and education campaigns, misconceptions are being dispelled. Patients are now more inclined to seek help and diagnosis for their symptoms, contributing to the growth of the lymphedema diagnostics market.

Medical professionals play a critical role in the diagnosis and management of lymphedema. As awareness increases, healthcare providers are better equipped to identify the condition, even in its early stages. This results in more referrals for diagnostic services and early intervention.

Increased education about lymphedema empowers patients to be proactive about their health. Patients who understand the risks and symptoms of lymphedema are more likely to seek early diagnosis and treatment, thereby driving the demand for diagnostic services.

In the digital age, information about health conditions is more accessible than ever. Patients can research lymphedema online, leading to better self-advocacy and increased awareness. They can then have informed discussions with their healthcare providers about the need for diagnostic evaluations.

Advocacy groups and healthcare organizations are actively engaged in raising awareness about lymphedema. These campaigns help individuals recognize the symptoms and understand the importance of early diagnosis and management, encouraging them to seek diagnostic services.

Healthcare institutions, including hospitals and clinics, are increasingly investing in the training and development of their medical staff in the field of lymphedema. This specialized knowledge equips healthcare providers with the skills to accurately diagnose and manage lymphedema.

As awareness grows, so does the body of research related to lymphedema. This research leads to more publications and guidelines for diagnosis and treatment, further standardizing and improving diagnostic procedures.

Patient-Centered Care

Patient-centered care has evolved from being a buzzword to a guiding principle in modern healthcare. The approach places patients at the heart of their healthcare journey, empowering them to actively participate in their care decisions. This paradigm shift is significantly contributing to the growth of the Global Lymphedema Diagnostics Market.

Patient-centered care encourages patients to become informed about their health. This empowerment enables individuals to recognize the signs and symptoms of lymphedema and take proactive steps toward seeking diagnosis. Patients are more likely to request diagnostic evaluations when they play a central role in their care.

Patients have the opportunity to engage in shared decision-making with their healthcare providers. A patient-centered approach fosters open and honest conversations about the risks and benefits of lymphedema diagnostics, resulting in greater acceptance of diagnostic procedures.

Patients who are actively involved in their care are more likely to adhere to treatment and management plans. In the context of lymphedema, this includes faithfully following recommended diagnostic assessments, leading to greater demand for diagnostic services.

Lymphedema is not a one-size-fits-all condition, and patient-centered care recognizes this fact. Healthcare providers are more inclined to tailor diagnostic evaluations to the specific needs of each patient, improving the accuracy of diagnosis and the effectiveness of subsequent treatments.

Patient-centered care is aligned with the need for appropriate reimbursement policies. With patients actively participating in their care decisions, there is a stronger case for insurance and healthcare systems to cover the cost of lymphedema diagnostics, making them more accessible.

When patients are engaged in their care, they experience better outcomes. Patient satisfaction and positive experiences can lead to word-of-mouth recommendations, driving more individuals to seek diagnostic services for lymphedema.

Patient-centered care, including early diagnosis and management, can be cost-effective for healthcare systems. It may prevent the progression of lymphedema, reducing the need for more extensive and expensive treatments.

Key Market Challenges

Limited Awareness

Lymphedema is not as widely recognized as other medical conditions, leading to a lack of awareness among the general population. This hampers early diagnosis and intervention as patients may not recognize the signs of lymphedema until it has progressed significantly.

Complex Diagnosis

Diagnosing lymphedema can be challenging. While advancements in diagnostic technology have improved accuracy, it remains a complex condition with varying presentations. This can make it difficult to establish a standard diagnostic process.

High Cost of Diagnostic Equipment

The sophisticated equipment and technologies used in lymphedema diagnostics can be expensive. This can pose a financial barrier for healthcare facilities, especially in resource-constrained regions, limiting the availability of diagnostic services.

Key Market Trends

Portable and Wearable Devices

Portable and wearable diagnostic devices are becoming more popular. These devices allow patients to monitor their lymphatic health in real-time, offering early warnings and enabling better self-management of the condition. They can also facilitate telehealth consultations with healthcare providers.

Preventive Screening

Early intervention is crucial in lymphedema management. Preventive screening programs, often integrated with cancer care, are becoming more prevalent. These screenings aim to identify patients at risk of lymphedema before symptoms become apparent, facilitating earlier diagnosis.

Genetic and Biomarker Testing

Research into the genetic and molecular underpinnings of lymphedema is advancing. Genetic and biomarker testing may help identify individuals at risk for developing lymphedema, allowing for more targeted and personalized diagnostic approaches.

Segmental Insights

Technology Insights

Based on the category of Technology, Lymphoscintigraphy is poised to capture a substantial market share within the Global Lymphedema Diagnostics Market during the forecast period for several compelling reasons. This imaging technique offers a non-invasive and highly accurate means of diagnosing and assessing lymphedema, a chronic and debilitating condition characterized by lymphatic system dysfunction. The method's ability to provide a clear visualization of lymphatic vessels and identify blockages, abnormalities, or impaired lymph flow is a crucial diagnostic tool for healthcare professionals. Furthermore, Lymphoscintigraphy's growing popularity can be attributed to its cost-effectiveness, minimal patient discomfort, and widespread availability. As the global awareness of lymphedema and the need for early and accurate diagnosis continue to rise, the demand for Lymphoscintigraphy as a diagnostic tool is expected to experience substantial growth, consolidating its position in the global market.

Regional Insights

North America dominated the Global Lymphedema Diagnostics Market for several compelling reasons. Firstly, the region boasts a well-established healthcare infrastructure and high healthcare expenditure, enabling widespread access to advanced diagnostic technologies and treatments. Additionally, North America places a strong emphasis on medical research and innovation, with a multitude of academic and research institutions continually advancing the field of lymphedema diagnostics. Moreover, the region has a growing aging population, which is more susceptible to lymphedema, thereby increasing the demand for diagnostic services. The robust presence of healthcare insurance and reimbursement policies in North America further facilitates patient access to diagnostic procedures. Furthermore, a heightened awareness of the importance of early lymphedema diagnosis and management has led to significant market growth in the region. As a result, North America is expected to maintain its dominant position in the global lymphedema diagnostics market during the forecast period.

Key Market Players

Shimadzu Corp

Fluoptics SAS

Bio Compression Systems Inc

Lohmann & Rauscher International GmbH & Co KG

Mego Afek A.C. Ltd.

Sigvaris Inc

PAUL HARTMANN AG

Stryker Corp

Cardinal Health Inc

ConvaTec Inc

Report Scope:

In this report, the Global Lymphedema Diagnostics Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Lymphedema Diagnostics Market, By Technology:

Bioimpedance Analysis Computed Tomography Lymphoscintigraphy Magnetic Resonance Imaging Near-Infrared Fluorescence Imaging Ultrasound Imaging X-Ray Lymphography

Lymphedema Diagnostics Market, By Disease:

Cancer Cardiovascular Disease Inflammatory Diseases

Lymphedema Diagnostics Market, By End User:

Diagnostic Centers Hospitals Research & Academic Institutes Others

Lymphedema Diagnostics Market, By Region:

North America
• United States
• Canada
• Mexico
Europe
• Germany
• United Kingdom
• France
• Italy
• Spain
Asia-Pacific
• China
• Japan
• India
• Australia
• South Korea
South America
• Brazil
• Argentina
• Colombia
Middle East & Africa
• South Africa
• Saudi Arabia
• UAE
• Kuwait

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Lymphedema Diagnostics Market.

Available Customizations:

Global Lymphedema Diagnostics Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Lymphedema Diagnostics Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Technology (Bioimpedance Analysis, Computed Tomography, Lymphoscintigraphy, Magnetic Resonance Imaging, Near-Infrared Fluorescence Imaging, Ultrasound Imaging, X-Ray Lymphography)
  • 5.2.2. By Disease (Cancer, Cardiovascular Disease, Inflammatory Diseases)
  • 5.2.3. By End User (Diagnostic Centers, Hospitals, Research & Academic Institutes, Others)
  • 5.2.4. By Region
  • 5.2.5. By Company (2023)
• 5.3. Product Market Map
  • 5.3.1. By Technology
  • 5.3.2. By Disease
  • 5.3.3. By End User
  • 5.3.4. By Region

6. North America Lymphedema Diagnostics Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Technology (Bioimpedance Analysis, Computed Tomography, Lymphoscintigraphy, Magnetic Resonance Imaging, Near-Infrared Fluorescence Imaging, Ultrasound Imaging, X-Ray Lymphography)
  • 6.2.2. By Disease (Cancer, Cardiovascular Disease, Inflammatory Diseases)
  • 6.2.3. By End User (Diagnostic Centers, Hospitals, Research & Academic Institutes, Others)
  • 6.2.4. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Lymphedema Diagnostics Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Technology
      • 6.3.1.2.2. By Disease
      • 6.3.1.2.3. By End User
  • 6.3.2. Canada Lymphedema Diagnostics Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Technology
      • 6.3.2.2.2. By Disease
      • 6.3.2.2.3. By End User
  • 6.3.3. Mexico Lymphedema Diagnostics Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Technology
      • 6.3.3.2.2. By Disease
      • 6.3.3.2.3. By End User

7. Europe Lymphedema Diagnostics Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Technology (Bioimpedance Analysis, Computed Tomography, Lymphoscintigraphy, Magnetic Resonance Imaging, Near-Infrared Fluorescence Imaging, Ultrasound Imaging, X-Ray Lymphography)
  • 7.2.2. By Disease (Cancer, Cardiovascular Disease, Inflammatory Diseases)
  • 7.2.3. By End User (Diagnostic Centers, Hospitals, Research & Academic Institutes, Others)
  • 7.2.4. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Lymphedema Diagnostics Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Technology
      • 7.3.1.2.2. By Disease
      • 7.3.1.2.3. By End User
  • 7.3.2. United Kingdom Lymphedema Diagnostics Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Technology
      • 7.3.2.2.2. By Disease
      • 7.3.2.2.3. By End User
  • 7.3.3. France Lymphedema Diagnostics Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Technology
      • 7.3.3.2.2. By Disease
      • 7.3.3.2.3. By End User
  • 7.3.4. Italy Lymphedema Diagnostics Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Technology
      • 7.3.4.2.2. By Disease
      • 7.3.4.2.3. By End User
  • 7.3.5. Spain Lymphedema Diagnostics Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Technology
      • 7.3.5.2.2. By Disease
      • 7.3.5.2.3. By End User

8. Asia-Pacific Lymphedema Diagnostics Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Technology (Bioimpedance Analysis, Computed Tomography, Lymphoscintigraphy, Magnetic Resonance Imaging, Near-Infrared Fluorescence Imaging, Ultrasound Imaging, X-Ray Lymphography)
  • 8.2.2. By Disease (Cancer, Cardiovascular Disease, Inflammatory Diseases)
  • 8.2.3. By End User (Diagnostic Centers, Hospitals, Research & Academic Institutes, Others)
  • 8.2.4. By Country
• 8.3. Asia-Pacific: Country Analysis
  • 8.3.1. China Lymphedema Diagnostics Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Technology
      • 8.3.1.2.2. By Disease
      • 8.3.1.2.3. By End User
  • 8.3.2. Japan Lymphedema Diagnostics Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Technology
      • 8.3.2.2.2. By Disease
      • 8.3.2.2.3. By End User
  • 8.3.3. India Lymphedema Diagnostics Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Technology
      • 8.3.3.2.2. By Disease
      • 8.3.3.2.3. By End User
  • 8.3.4. Australia Lymphedema Diagnostics Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Technology
      • 8.3.4.2.2. By Disease
      • 8.3.4.2.3. By End User
  • 8.3.5. South Korea Lymphedema Diagnostics Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Technology
      • 8.3.5.2.2. By Disease
      • 8.3.5.2.3. By End User

9. South America Lymphedema Diagnostics Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Technology (Bioimpedance Analysis, Computed Tomography, Lymphoscintigraphy, Magnetic Resonance Imaging, Near-Infrared Fluorescence Imaging, Ultrasound Imaging, X-Ray Lymphography)
  • 9.2.2. By Disease (Cancer, Cardiovascular Disease, Inflammatory Diseases)
  • 9.2.3. By End User (Diagnostic Centers, Hospitals, Research & Academic Institutes, Others)
  • 9.2.4. By Country
• 9.3. South America: Country Analysis
  • 9.3.1. Brazil Lymphedema Diagnostics Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Technology
      • 9.3.1.2.2. By Disease
      • 9.3.1.2.3. By End User
  • 9.3.2. Argentina Lymphedema Diagnostics Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Technology
      • 9.3.2.2.2. By Disease
      • 9.3.2.2.3. By End User
  • 9.3.3. Colombia Lymphedema Diagnostics Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Technology
      • 9.3.3.2.2. By Disease
      • 9.3.3.2.3. By End User

10. Middle East and Africa Lymphedema Diagnostics Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Technology (Bioimpedance Analysis, Computed Tomography, Lymphoscintigraphy, Magnetic Resonance Imaging, Near-Infrared Fluorescence Imaging, Ultrasound Imaging, X-Ray Lymphography)
  • 10.2.2. By Disease (Cancer, Cardiovascular Disease, Inflammatory Diseases)
  • 10.2.3. By End User (Diagnostic Centers, Hospitals, Research & Academic Institutes, Others)
  • 10.2.4. By Country
• 10.3. MEA: Country Analysis
  • 10.3.1. South Africa Lymphedema Diagnostics Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Technology
      • 10.3.1.2.2. By Disease
      • 10.3.1.2.3. By End User
  • 10.3.2. Saudi Arabia Lymphedema Diagnostics Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Technology
      • 10.3.2.2.2. By Disease
      • 10.3.2.2.3. By End User
  • 10.3.3. UAE Lymphedema Diagnostics Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Technology
      • 10.3.3.2.2. By Disease
      • 10.3.3.2.3. By End User
  • 10.3.4. Kuwait Lymphedema Diagnostics Market Outlook
    • 10.3.4.1. Market Size & Forecast
      • 10.3.4.1.1. By Value
    • 10.3.4.2. Market Share & Forecast
      • 10.3.4.2.1. By Technology
      • 10.3.4.2.2. By Disease
      • 10.3.4.2.3. By End User

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Recent Development
• 12.2. Mergers & Acquisitions
• 12.3. Product Launches

13. Porter's Five Forces Analysis

• 13.1. Competition in the Industry
• 13.2. Potential of New Entrants
• 13.3. Power of Suppliers
• 13.4. Power of Customers
• 13.5. Threat of Substitute Products

14. Competitive Landscape

• 14.1. Shimadzu Corp
  • 14.1.1. Business Overview
  • 14.1.2. Product Offerings
  • 14.1.3. Recent Developments
  • 14.1.4. Financials (As Reported)
  • 14.1.5. Key Personnel
  • 14.1.6. SWOT Analysis
• 14.2. Fluoptics SAS
• 14.3. Bio Compression Systems Inc
• 14.4. Lohmann & Rauscher International GmbH & Co KG
• 14.5. Mego Afek A.C. Ltd.
• 14.6. Sigvaris Inc
• 14.7. PAUL HARTMANN AG
• 14.8. Stryker Corp
• 14.9. Cardinal Health Inc
• 14.10. ConvaTec Inc

15. Strategic Recommendations

16. About Us & Disclaimer